Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
-
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
-
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
-
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
-
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
-
Kleo Teams Up with Londis to Enhance Convenience Store Operations with Advanced EPOS and MPOS Solutions
-
Platform Science to Acquire Trimble's Global Transportation Telematics Business Units to Drive the Future of Transportation In-Cab Technology
-
Platform Science to Acquire Trimble’s Global Transportation Telematics Business Units to Drive the Future of Transportation In-Cab Technology
-
Rotev Wins Praise for Breakthrough Web Design Service Tailored to Deliver Results
-
KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions
-
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
-
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
-
Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024
-
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
-
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
-
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
-
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
-
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
-
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
-
Lewis Access Proudly Introduces its New Range of Premium Access Solutions - Made in the UK
-
XinKailian Biotechnology Unveils GMP-Certified Ubiquinol with Patent Safety, Set for Debut at Vitafoods Asia 2024
-
At Congressional Black Caucus Foundation's Phoenix Awards, President Biden And Vice President Harris Urge Caucus To Advance Their Vision For The Future Ahead Of The Presidential Election.
-
AHelp Launches Chrome Extension to Assist Users in Improving Academic Workflow with AI Tools
-
Uzbekistan Announces Global Speaker Lineup for 2024 World Conference on Creative Economy in Tashkent
-
MAX Power Mining Corp. Announces Results of Annual General and Special Meeting
-
The 3rd International Summit for Mayors of Rural Tourism Villages & the Forum of Best Tourism Villages is Coming to Huangling, Wuyuan
-
CNOOC Limited Successfully Withstands Super Typhoon "Yagi"
-
Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together
-
Exploring the Hidden Gems of Glendale's History Museum
-
Momcozy launches Brand Day Campaign and New Initiatives, Empowering Moms Through Cozy Evolution
-
PRESIDENT JOE BIDEN AND VICE PRESIDENT KAMALA D. HARRIS TO CELEBRATE HISPANIC HERITAGE MONTH AT THE 2024 CONGRESSIONAL HISPANIC CAUCUS INSTITUTE LEADERSHIP CONFERENCE AND 47TH ANNUAL AWARDS GALA
-
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
-
Masimo Partners with Qualcomm to Develop Next-Generation Smartwatch Reference Platform for Original Equipment Manufacturers
-
Cierto Tequila Wins Tequila of the Year at the 2024 Melbourne International Spirits Competition
-
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
-
Cierto Tequila Named Tequila of the Year at the 2024 Asia International Spirits Competition
-
Rhino Rescue Marks World First Aid Day with Launch of Outdoor-Specific First Aid Kits
-
Murray Lampert Design, Build, Remodel: Maximizing Your Home's Potential: The San Diego Remodeling Guide
-
The Yadot Group to Acquire Experiential Agency Socials Dallas
-
35/2024・Trifork Group AG – Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them
-
SINEXCEL and FastCharge.me Forge Partnership for EV Charging Solutions
-
Balancing Function and Beauty: How Dental Crowns Contribute to a Healthy, Attractive Smile
-
Best Gold IRA Companies in the US 2024 Rankings Announced
-
Dongfeng Embarks on a New Journey in Europe, Various New Products Debuted Offer Diversified Mobility Options
-
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unre
-
Holiday Cheer Takes Center Stage: USPS Unveils Festive Holiday Stamps at National Postal Museum
-
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
-
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
-
AI revolutionizes industry classification at Hacking Big Numbers Hackathon
-
Gold IRA vs Physical Gold: Key Differences Explained by an Expert
